HIV-GRADE: A publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge

Intervirology

Volumn 55, Issue 2, 2012, Pages 102-107

  Obermeier, Martin ^a   Pironti, Alejandro ^l   Berg, Thomas ^a   Braun, Patrick ^c   Däumer, Martin ^d   Eberle, Josef ^e   Ehret, Robert ^c   Kaiser, Rolf ^g   Kleinkauf, Niels ^b   Korn, Klaus ^h   Kücherer, Claudia ^b   Müller, Harm ⁱ   Noah, Christian ^j   Stürmer, Martin ^k   Thielen, Alexander ^d,l   Wolf, Eva ^f   Walter, Hauke ^h  

^a Medizinisches Labor Dr Berg   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c Praxen Zentrum Blondelstrasse   (Germany)

^d Institut fur Immunologie und Genetik   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f MUC Research GmbH and MVZ Karlsplatz   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁱ Labor Fenner   (Germany)

^j Labor Lademannbogen   (Germany)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^l MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

more..

Author keywords

Clinical validation; Genotypic drug resistance; HIV GRADE

Indexed keywords

ALGORITHM; ANTIVIRAL RESISTANCE; ARTICLE; BIOINFORMATICS; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS LOAD; VIRUS MUTATION;

ALGORITHMS; ANTI-HIV AGENTS; COMPUTATIONAL BIOLOGY; GERMANY; HIV INFECTIONS; HIV-1; HUMANS; INTERNET; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING;

EID: 84856432470     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000331999     Document Type: Article

References (34)

1. Boyd MA, Hill AM: Clinical management of treatment-experienced, HIV/AI-graveS patients in the combination antiretroviral therapy era. Pharmacoeconomics 2010;28(suppl 1):17-34.
2. Preston B-grave, Poiesz BJ, Loeb LA: Fidelity of HIV-1 reverse transcriptase. Science 1988;242:1168-1171.
3. Miller V, de Béthune MP, Kober A, Stürmer M, Hertogs K, Pauwels R, et al: Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 1998;42:3123-3129.
4. De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, et al: Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. Antivir Ther (Lond.) 2011;16:489-497.
5. Götte M, Wainberg MA: Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resist Updat 2000;3:30-38.
6. Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R, Hoffmann D, et al: Tenofovir resistance and resensitization. Antimicrob Agents Chemother 2003;47:3478-3484.
7. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, González J, et al: Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AI-graveS 2002;16:209-218.
8. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al: Drug-resistance genotyping in HIV-1 therapy: the VIRA-graveAPT randomised controlled trial. Lancet 1999;353:2195-2199.
9. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AI-graveS 2002;16:369-379.
10. Meynard J-L, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al: Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AI-graveS 2002;16:727-736.
11. Vercauteren J, Vandamme A-M: Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antivir Res 2006;71:335-342.
12. Beerenwinkel N, Däumer M, Oette M, Korn K, Hoffmann D, Kaiser R, et al: Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003;31:3850-3855.
13. HIV Drug Resistance Database. http://hivdb.stanford.edu/(accessed July 5, 2011).
14. HIV-GRA-graveE: Homepage. http://www.hivgrade. de/cms/grade/(accessed July 5, 2011).
15. Huang X, Zhang J: Methods for comparing a DNA sequence with a protein sequence. Comput Appl Biosci 1996;12:497-506.
16. Betts BJ, Shafer RW: Algorithm specification interface for human immunodeficiency virus type 1 genotypic interpretation. J Clin Microbiol 2003;41:2792-2794.
17. HIV French Resistance - HIV-1 genotypic drug resistance interpretation's algorithms. http://www.hivfrenchresistance.org/(accessed July 5, 2011).
18. Lab: Rega HIV drug resistance algorithms. http://jose.med.kuleuven. be/lab/index. php?id=30 (accessed July 5, 2011).
19. Geno2pheno resistance. http://www.geno2pheno.org/(accessed July 5, 2011).
20. Prosperi MC, Di Giambenedetto S, Fanti I, Meini G, Bruzzone B, Callegaro A, et al: A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen. BMC Med Inform Decis Mak 2011;11:40.
21. Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, et al: Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. J. Antimicrob Chemother 2009;64:616-624.
22. Team R-graveC. R: A language and environment for statistical computing. Vienna, 2009. http://www.R-project.org.
23. Feng JY, Ly JK, Myrick F, Goodman D, White KL, Svarovskaia ES, et al: The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 2009;6:44.
24. Pingen M, Nijhuis M, de Bruijn JA, Boucher CAB, Wensing AMJ: Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 2011;66:1467-1480.
25. Verhofstede C, Wanzeele FV, van der Gucht B, de Cabooter N, Plum J: Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitorsensitive genotype. AI-graveS 1999;13:2541-2546.
26. Walter H, Löw P, Harrer T, Schmitt M, Schwingel E, Tschochner M, et al: No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual. J Acquir Immune Defic Syndr 2002;31:137-146.
27. Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, et al: The LOPSAQ study:48-week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother 2006;58:1024-1030.
28. Wiesmann F, Vachta J, Ehret R, Walter H, Kaiser R, Stürmer M, et al: The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors atazanavir and saquinavir: is there a clinical advantage? AI-graveS Res Ther 2011;8:7.
29. Altmann A, Rosen-Zvi M, Prosperi M, Aharoni E, Neuvirth H, Schülter E, et al: Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy. PLoS ONE 2008;3:e3470.
30. EuResist Data Analysis. http://engine.euresist.org/(accessed July 5, 2011).
31. Zazzi M, Kaiser R, Sönnerborg A, Struck D, Altmann A, Prosperi M, et al: Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). HIV Med 2011;12:211-218.
32. Prosperi MCF, Altmann A, Rosen-Zvi M, Aharoni E, Borgulya G, Bazso F, et al: Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antivir Ther (Lond.) 2009;14:433-442.
33. Lengauer T: Bioinformatical assistance of selecting anti-HIV therapies: where do we stand? Intervirology 2012;55:108-112.
34. Altmann A, Däumer M, Beerenwinkel N, Peres Y, Schülter E, Büch J, et al: Predicting the response to combination antiretroviral therapy: retrospective validation of geno-2pheno-THEO on a large clinical database. J Infect Dis 2009;199:999-1006.